High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis

American Journal of Hematology

Volumn 79, Issue 1, 2005, Pages 26-35

  Graf, Michaela ^a   Reif, Susanne ^a   Hecht, Karin ^a   Pelka Fleischer, Renate ^a   Pfister, Karin ^b   Schmetzer, Helga ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Acute myeloid leukemia; CD87; Immunophenotyping; Prognosis; Urokinase plasminogen activator receptor

Indexed keywords

ANTIBODY; ANTIGEN; CD87 ANTIGEN; CYTARABINE; DAUNORUBICIN; MEMBRANE PROTEIN; MITOXANTRONE; PHYCOERYTHRIN; PLASMIN; TIOGUANINE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CELL TYPE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR DENSITY; SURVIVAL TIME; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

ADULT; AGED; ANTIGENS, CD; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; GENETIC MARKERS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 18044398758     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20337     Document Type: Article

References (22)

1. Lijnen HR. Pathophysiology of the plasminogen-plasmin system. Int J Clin Lab Res 1996;26:1-6.
2. Stephans S, Yamamoto B. Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience 1996;72(3):593-600.
3. Plesner T, Ploug M, Ellis V, et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994;83:808-815.
4. Lanza F, Castoldi GL, Castagnari B, et al. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukemic cells. Br J Haematol 1998;103:110-123.
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33(4):451-458.
6. Bene MC, Bernier M, Castoldi G, et al. Proposals for the immunological classification of acute leukaemias. Leukemia 1995;9:1783-1788.
7. Rothe G, Schmitz G (Working group on Flow cytometry and Image Analyses). Consensus protocol for the flow-cytometric immunophenotying of hematopoietic malignancies. Leukemia 1996;10:877-895.
8. Mitelman K. ISCN. An international system for human cytogenetic nomenclature. Basel, Switzerland: Karger; 1995.
9. Mrozek K, Heinonen K, de la Chapelle A, Boomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17-31.
10. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003;102(7):2395-2402.
11. Mazumdar M, Glassman JR. Tutorial in biostatistics. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatment. Stat Med 2000;19:113-132.
12. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 2004;72(2):89-106.
13. Mustjoki S, Alitalo R, Stephens R, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. Thromb Haemost 1999;81:705-710.
14. Kern W, Danhauser-Riedl S, Ratei R, et al. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003;88(6):646-653.
15. Simon D, Rao N, Yu H, et al. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996;88:3185-3194.
16. Castagnari B, Moretti S, Latorraca A, et al. Flow cytometry evaluation of urokinase-type plasminogen activator receptor (UPA-R) in acute myeloid leukemia cells. Boll Soc Ital Biol Sper 1995;71(5-6):141-147.
17. Reuning U, Magdolen V, Hapke S, Schmitt M. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem 2003;384(8):1119-1131.
18. Schmetzer HM, Wilmanns W, Gerhartz HH. Detection of acute myeloid leukemic cells in complete remission and in extramedullary sites by clonal analyses. Acta Haematol 1996;96(2):83-87.
19. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997;78:285-296.
20. Champelovier P, Boucard N, Levacher G, Simon A, Seigneurin D, Praloran V. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urol Res 2002;30(5):301. Epub 2002 Aug 15.
21. Togel F, Datta C, Badbaran A, et al. Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells. J Hematother Stem Cell Res 2001;10(1):141-145.
22. Thewes M, Elsner E, Wessner D, Engst R, Ring J. The urokinase plasminogen activator system in angiosarcoma, Kaposi's sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study. Int J Dermatol 2000;39(3):188-191.